In vitro antifungal oral drug and drug-combination activity against onychomycosis causative dermatophytes

Medical Mycology

Volumn 44, Issue 4, 2006, Pages 357-362

  Santos, Daniel A ^a   Hamdan, J S ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Dermatophytes; Drug combination; Susceptibility tests; Synergism

Indexed keywords

ANTIFUNGAL AGENT; CICLOPIROXOLAMINE; FLUCONAZOLE; GRISEOFULVIN; ITRACONAZOLE; KETOCONAZOLE; TERBINAFINE;

ARTICLE; CONTROLLED STUDY; CULTURE MEDIUM; DERMATOPHYTE; FUNGAL STRAIN; FUNGUS GROWTH; FUNGUS ISOLATION; IN VITRO STUDY; INOCULATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; SPECIES DIFFERENCE; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TOENAIL ONYCHOMYCOSIS; TRICHOPHYTON MENTAGROPHYTES; TRICHOPHYTON RUBRUM;

ADMINISTRATION, ORAL; ANTIFUNGAL AGENTS; DRUG RESISTANCE, FUNGAL; DRUG SYNERGISM; HUMANS; MICROBIAL SENSITIVITY TESTS; ONYCHOMYCOSIS; TRICHOPHYTON;

ARTHRODERMA BENHAMIAE; ARTHRODERMATACEAE; TRICHOPHYTON RUBRUM;

EID: 33745278875     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.1080/13693780500536893     Document Type: Article

References (20)

1. Kokjohn, K and Bradley, M and Griffiths, B and Ghannoum, M. (2003) Evaluation of in vitro activity of ciclopirox olamine, butenafine HCl and econazole against dermatophytes and bacteria Int J Dermatol, 42, pp. 11-17.
2. KortingHC, OllertM, AbeckD, for the GCDDSS Group. Results of german multicenter study of antimicrobial susceptibilities of Trichophyton rubrum and Trichophyton mentagrophytes strains causing tinea unguium. Antimicrob Agents Chemother 1995; 39: 1206-1208.
3. Faergemann, J and Baran, R. (2003) Epidemiology, clinical presentation and diagnosis of onychomycosis Br J Dermatol, 65, pp. 1-4.
4. Hay, RJ. (2001) The future of onychomycosis therapy may involve a combination of approaches Br J Dermatol, 145, pp. 3-8.
5. Seebacher, C. (2003) The change of dermatophyte spectrum in dermatomycoses Mycoses, 46, pp. 42-46.
6. Scher, RK and Baran, R. (2003) Onychomycosis in clinical practice: factors contributing to recurrence Br J Dermatol, 149, pp. 5-9.
7. Evans, EGV. (2003) Drug synergies and the potential for combination therapy in onychomycosis Br J Dermatol, 149, pp. 11-13.
8. Lecha, M. (2001) Amorolfine and itraconazole combination for severe toenail onychomycosis; results of an open randomized trial in Spain Br J Dermatol, 145, pp. 21-26.
9. National Committee for Clinical Laboratory Standards.(2002) Reference method for broth dilution antifungal susceptibility testing of filamentous fungi: Approved Standard M38-A. Wayne PA: National Committee for Clinical Laboratory Standards.
10. Santos, DA and Hamdan, JS. (2005) Evaluation of broth microdilution antifungal susceptibility testing conditions for Trichophyton rubrum J Clin Microbiol, 43, pp. 1917-1920.
11. Gupta, AK and Kohli, Y. (2003) In vitro susceptibility testing ciclopirox, terbinafine, ketoconazole and itraconazole against dermatophytes and nondermatophytes, and in-vitro evaluation of combination antifungal activity Br J Dermatol, 149, pp. 296-305.
12. Barry, AL and Pfaller, MA and Brown, SD and (2005) Quality control limits of broth microdilution susceptibility tests of ten antifungal agents J Clin Microbiol, 38, pp. 3457-3459.
13. Nimura, K and Niwano, Y and Ishiduka, S and Fukumoto, R. (2001) Comparison of In vitro antifungal activities of topical antimycotics launched in 1990s in Japan Int J Antimicrob Agents, 18, pp. 173-178.
14. Fernández-Torres, B and Cabanes, FJ and Carrillo-Muñoz, A and et al. (2002) Collaborative evaluation of optimal antifungal susceptibility testing conditions for dermatophytes J Clin Microbiol, 40, pp. 3999-4003.
15. Develoux, M. (2001) Griseofulvin Ann Dermatol Venereol, 128, pp. 1317-1325.
16. Artis, WM and Odle, BM and Jones, HE. (1981) Griseofulvin-resistant dermatophytosis correlates with In vitro resistance Arch Dermatol, 117, pp. 16-19.
17. Lacaz CS, Porto E, Martins JEC, Heins-Vaccari EM, Melo NT. 2002. Drogas antifúngicas. Terapêutica das micoses superficiais. Provas de sensibilidade in vitro. Dosagem sanguínea. In Tratado de Micologia Médica Lacaz. 9th ed. São Paulo: Sarvier, 2002: 998-1061.
18. Olafsson, JH and Sigurgeirsson, B and Baran, R. (2003) Combination therapy for onychomycosis Br J Dermatol, 149, pp. 15-18.
19. Baran, R. (2001) Topical amorolfine for 15 months combined with 12 weeks of oral terbinafine, a cost-effective treatment for onychomycosis Br J Dermatol, 141, pp. 21-26.
20. Gomez-Lopez, A and Cuenca-Estrella, M and Mellado, E and Rodriguez-Tudela, JL. (2003) In vitro evaluation of combination of terbinafine with itraconazole or amphotericin B against Zygomycota Diagn Microbiol Infect Dis, 45, pp. 199-202.